Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bapotulimab (BAY1905254) +/- Pembrolizumab in Advanced Solid Tumors
NCT03666273Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2018
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bapotulimab in solid tumor (advanced stage) and head and neck squamous cell carcinoma (HNSCC), sponsored by Bayer. Primary endpoints: Incidence of treatment-emergent Adverse Events up to 58 months, Severity of treatment-emergent Adverse Events up to 58 months and 3 more. Started Sep 2018; status: completed.
02
Drugs
bapotulimab
03
Conditions
solid tumor (advanced stage)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03666273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666273.